DOI:
10.1055/s-00000125
Senologie - Zeitschrift für Mammadiagnostik und -therapie
LinksClose Window
References
Stebbing J, Baranau YV, Baryash V. et al.
Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer.
ASCO 2017 Poster 510
Access:
We do not assume any responsibility for the contents of the web pages of other providers.